LIZTOX® 100u

LIZTOX® 100u is a botulinum toxin type A injectable product manufactured by Huons Biopharma, designed for temporary reduction of facial wrinkles, particularly glabellar lines and lateral canthal lines (crow’s feet). The active ingredient, Clostridium botulinum toxin type A, works by blocking the release of acetylcholine at neuromuscular junctions, leading to temporary paralysis of the targeted facial muscles. Clinically tested for safety and efficacy, LIZTOX® has shown non-inferiority compared to other established toxins. The results typically last 3 to 4 months, with visible improvement observed as early as 4 weeks post-injection.

• Type: Purified botulinum toxin type A
• Indication: Aesthetic wrinkle reduction in adults aged 19–65
• Duration of Effect: Approximately 3–4 months
• Form: Lyophilized powder for reconstitution

LIZTOX® should be reconstituted with sterile, preservative-free 0.9% saline and injected intramuscularly into the targeted facial muscles.

• Dilution: 100 units in 2.5 mL saline = 4 U per 0.1 mL
• Glabellar Lines:
  • Inject 0.1 mL into 5 sites (2 corrugator, 1 procerus) = 20 U
• Crow’s Feet:
  • Inject 0.1 mL into 3 sites per side of the orbicularis oculi = 24 U total
• Needle Gauge: 30G to 33G
• Effect Onset: Within 3–5 days
• Peak Effect: 2 weeks
• Duration: ~3–4 months
• Storage after reconstitution: Use within 24 hours (refrigerated at 2–8°C)

LIZTOX® is indicated for temporary improvement of dynamic facial wrinkles in adults between 19 and 65 years of age.

Indications:

• Glabellar lines (frown lines between the eyebrows)
• Lateral canthal lines (crow’s feet)

Contraindications:

• Known hypersensitivity to botulinum toxin or human albumin
• Presence of neuromuscular disorders (e.g., myasthenia gravis, ALS)
• Pregnancy or breastfeeding
• Infection or skin disease at the injection site

Warnings:

• Risk of ptosis if injected too close to the levator palpebrae superioris
• Risk of systemic toxin spread causing respiratory or swallowing difficulties
• Caution in patients using muscle relaxants or aminoglycosides

LIZTOX® contains a purified neurotoxic protein complex with excipients to maintain product stability and solubility.

• Active Ingredient: Clostridium botulinum toxin type A – 100 Units
• Excipients:
  • Human serum albumin
  • Sodium chloride
• Form: Freeze-dried white powder
• Reconstitution Medium: Preservative-free 0.9% saline

LIZTOX® is supplied as a single-use vial with clear dosing and reconstitution guidance.

• Contents:
  • 1 x vial with 100 units lyophilized powder
• Packaging Type: Clear, sterile glass vial
• Application Form: Prescription-only drug
• Shelf Code: Korean MFDS item code: 201605990

LIZTOX® is generally well tolerated; however, some localized and systemic side effects have been reported.

• Common (≥1%):
  • Injection site bruising
  • Nasopharyngitis
  • Headache or localized pain
  • Eyelid drooping (ptosis)
• Less Common (<1%):
  • Hypersensitivity reactions (rash, urticaria)
  • Muscle weakness near injection site
  • Cystitis, gastrointestinal upset, or dizziness
• Rare:
  • Anaphylaxis, myocardial infarction, vocal changes
• Post-Marketing:
  • Drooping eyelids, rash, localized muscle weakness

Proper storage of LIZTOX® is essential to maintain sterility and effectiveness.

• Unopened: Store refrigerated at 2–8°C
• After Reconstitution: Use within 24 hours, keep refrigerated
• Do Not Freeze
• Handling Precautions:
  • Avoid vigorous shaking
  • Dispose of vials using medical waste protocols
  • In case of spillage, deactivate with 0.5–1% hypochlorite solution